

**CURRICULUM VITAE**  
**ELAINE H. MORRATO**

**ADDRESS**

University of Colorado Denver  
12477 East 19<sup>th</sup> Avenue  
Building 406, Room T09-105  
Mail Stop F443  
Aurora, CO 80045-0508  
303-724-1535 (phone)  
303-724-1934 (fax)  
Email: elaine.morrato@ucdenver.edu

**EDUCATION**

- 2008 Board Certification in Public Health, National Board of Public Health Examiners
- 2006 Dr.P.H., General Epidemiology, The Johns Hopkins University, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Dissertation: Impact of nefazodone (Serzone®) hepatic risk minimization recommendations: a case study evaluation of an FDA Boxed Warning.
- 2003 M.P.H., Epidemiology, The Johns Hopkins University, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Masters Capstone Project: FDA pediatric drug policy: Characteristics of drugs granted exclusivity.
- 1988 B.S. (Honors) summa cum laude, Biology/Biochemistry, Purdue University, West Lafayette, IN. Honors thesis: Spectral analysis of thermodynamic properties in non-Watson-Crick base pairing and DNA secondary structure.

**PROFESSIONAL EXPERIENCE**

- 2009- Assistant Director, Children's Outcomes Research (COR) Program, The Children's Hospital, Denver, CO [Senior Methodologist since 2006]
- 2006- Assistant Professor, Department of Health Systems, Management & Policy, Colorado School of Public Health (formerly in the Department of Preventive Medicine and Biometrics, School of Medicine), University of Colorado Denver, Aurora, CO
- 2006- Joint Appointment, Department of Pediatrics, University of Colorado Denver, Aurora, CO.
- 2006- Joint Appointment, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Denver, Aurora, CO.
- 2006- Member, Colorado Health Outcomes Program (COHO), University of Colorado Denver, Aurora, CO.
- 2003-2006 Fellow, Outcomes Research Program, Department of Clinical Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO
- 2004-2005 Vice President, Health Care New Business Development, Pharmaceutical and Wellness Market Research Services, Information Resources, Inc., Chicago, IL.

2002-2003	Student Research Associate, Office of Drug Safety, U.S. Food and Drug Administration, Rockville, MD. Project: Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
2000-2002	Section Head, Global Risk Management Team Leader, Cardiovascular New Drug Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
2000-2002	Section Head, Global Phase III Project Leader, Cardiovascular New Drug Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
1997-2000	Section Head, Global Phase IIIb/IV Project Leader, Cardiac Technical Brand Manager, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
1996-1997	Section Head, U.S. Launch Team Leader for Helidac® (tetracycline, metronidazole, bismuth-subsalicylate), North America Product Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
1994-1997	Section Head, Technical Brand Manager, Asacol® (mesalamine) and Macrobid® (nitrofurantoin monohydrate/macrocrystals), North America Product Development, Pharmaceutical Division, The Procter & Gamble Company, Cincinnati, OH.
1993-1994	Senior Scientist, Global Products Research Team Leader for Over-the Counter Cholesterol-Lowering Drugs, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
1992-1993	Senior Scientist, National Product Launch Team Leader, Metamucil® Sunrise Smooth Sugar-Free Regular Flavor, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
1988-1992	Scientist, Professional Oral Care Products, Health Care Product Development, The Procter & Gamble Company, Cincinnati, OH.
1987	Research Intern, Mammalian cell culture and pharmaceutical research, Monsanto Chemical Company, St. Louis, MO.
1986	Market Research Interviewer, Monsanto Agricultural Company, St. Louis, MO.

## PROFESSIONAL ACTIVITIES

### *Professional Societies*

2007-	Member, American Diabetes Association
2005-	Member, International Society for Pharmacoepidemiology
2005-8	Member, International Society for Pharmacoeconomics and Outcomes Research

### *Work Groups / Committees*

2009-2012	Member, Faculty Council, Colorado School of Public Health, University of Colorado Denver
2009	Consultant to the FDA Drug Safety and Risk Management Advisory Committee
2008-	Member, Scientific and Advisory Review Committee (SARC) of The Children's Hospital (TCH) Clinical Translational Research Center (CTRC) of the Colorado Clinical Translational Sciences Institute (CCTSI)
2008	Consultant to the FDA Risk Communication Advisory Committee

- 2006- Contributor, APA Workgroup on Antipsychotics and Metabolic Risk: APA Workgroup on Antipsychotics and Metabolic Risk. Newcomer JW, Blonde L, Ader M, Beaser R, Marder S, Nemeroff C
- 2006-2007 Co-Chair, Policy Advocacy Working Group, Retrospective Database Special Interest Group of the International Society for Pharmacoeconomics and Outcomes Research
- 2005-2006 Member, Policy Advocacy Working Group, Retrospective Database Special Interest Group of the International Society for Pharmacoeconomics and Outcomes Research

### **Consulting**

- 2006 Training. Workshop on Pharmaceutical RiskMAP Evaluation. (b) (4).
- 2004 Study design consultant. (b) (4) on national consumer health opinions, health concerns, and diet and lifestyle habits in the U.S. (b) (4)
- 2003 Training. U.S. Pharmaceutical Market and FDA Regulation. (b) (4)
- 2002-2004 Study design and business development consultant (b) (4) a nationally representative consumer panel tracking over-the-counter and prescription drug purchases at the retail level in the U.S. (b) (4)
- 2002-2004 Business development consultant. “(b) (4) Healthcare Rx and OTC” business unit. (b) (4)

## **EDITORIAL ACTIVITIES**

### **Peer Review**

- 2009 Manuscript reviewer, *Archives of Internal Medicine*, *Journal of Child and Adolescent Psychopharmacology*, *American Journal of Managed Care*, *Social Psychiatry and Psychiatric Epidemiology*, and *Neuro-Psychopharmacology & Biological Psychiatry*
- 2008 Manuscript reviewer, *Journal of Clinical Psychopharmacology*, *Health Policy*, *American Journal of Psychiatry*, *Journal of Health Services Research and Policy*
- Symposium abstract reviewer, “Contributed Health Decisions Case Study”, *International Society for Pharmacoeconomics and Outcomes Research*
- 2007-2009 Abstract reviewer, *International Society for Pharmacoepidemiology*
- 2006 Manuscript reviewer, *Schizophrenia Bulletin*

## **HONORS AND AWARDS**

- 2006 Delta Omega Honorary Society in Public Health, The Johns Hopkins Bloomberg School of Public Health
- 2004 Campaign for Epidemiology Award, Johns Hopkins, Bloomberg School of Public Health
- 2003 Master of Public Health Capstone Award for Outstanding Achievement, Johns Hopkins, Bloomberg School of Public Health
- 1988 Helen B. Schleman Award for Women, top academic female graduates, Purdue University
- 1988 AWS Very Important Woman Award, top graduating female leaders, Purdue University

1988	School of Science Outstanding Senior, Department of Biology, Purdue University
1987	Mortar Board Honor Society for achievements in scholarship, leadership, and service, Purdue University
1987	Phi Beta Kappa Society, Purdue University
1987	American Chemical Society Award for Outstanding Junior in Analytical Chemistry, Purdue University
1986	Pi Sigma Alpha National Honor Society of Political Science, Purdue University
1985-1985	School of Science Research Scholarship, Purdue University
1984	National Presidential Scholar Finalist and National Merit Scholar

## PUBLICATIONS

### *Peer-reviewed Journal Articles*

**Morrato EH**, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Arch Gen Psych (in press)*

Banta JE, **Morrato EH**, Lee SW, Haviland MG. Retrospective Analysis of Diabetes Care in California Medicaid Patients with Mental Illness *Journal of General Internal Medicine*. May 5 [Epub ahead of print]

**Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the ADA's Statement on antipsychotic drugs and diabetes *Diabetes Care* 2009; 32(6): 1037-1042.

**Morrato EH**, Cuffel B, Newcomer JW, Lombard I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: A retrospective study of commercially insured patients. *Journal of Clinical Psychopharmacology*; 2009; 29(1): 26-32.

**Morrato EH**, Curbow B, Crum R, Nowels C, Feinleib, M. Communicating drug risk to physicians: challenges and opportunities. *International J of Risk & Safety in Medicine* 2008; 20(3): 143-154.

**Morrato EH**, Dillon P, Ziegler MM. Surgical outcomes research: A progression from performance audits, to assessment of administrative databases, to prospective risk-adjusted analysis. How far have we come? *Curr Opin Pediatr* June 1, 2008; 20(3): 320-325.

Dillon P, Hammermeister K, **Morrato EH**, Kempe A, Oldham K, Moss L, Marchildon M, Ziegler M, Steeger J, Rowell K, Shiloach M, Henderson W. Developing a NSQIP module to measure outcomes in children's surgical care: opportunity and challenge *Semin in Pediatr Surg* May 1, 2008; 17(2): 131-140.

**Morrato EH**, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population based study of Medicaid claims data. *J Clin Psychiatry*. 2008; 69(2):316-22.

**Morrato EH**, Libby AM, Orton HD, deGruy III, FV, Brent DA, Allen RR, Valuck RJ. Frequency of provider contact after FDA warning on suicidal risk of antidepressants in children. *Am J Psychiatry*. 2007; 10.1176/appi.ajp.2007.07010205).

**Morrato EH**, Elias M, Gericke, C. Population-based data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK, and USA. *Journal of Public Health*. 2007; doi:10.1093/pubmed/fdm065.

Valuck RJ, **Morrato EH**, Dodd S, Oderda G, Haxby DG, Allen RR. How expensive is antipsychotic polypharmacy? Experience from five state Medicaid programs. *Current Medical Research and Opinion*. 2007; 23(10): 2567-2576.

Valuck RJ, Libby AM, Orton HD, **Morrato EH**, Allen RR, Baldessarini RJ. Spillover effects on treatment of adult depression in primary care after FDA Advisory on risk of pediatric suicidality with SSRIs. *Am J Psychiatry*. 2007 Aug; 164(8):1198-1205.

Libby AM, Brent DJ, **Morrato EH**, Orton HD, Allen R, Valuck RJ. Pediatric depression treatment declines after FDA advisory on suicidality risk of SSRI antidepressants. *Am J Psychiatry*. 2007; 164: 884-891.

**Morrato EH**, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. Adults with diabetes and at-risk for developing diabetes, 2003. *Diabetes Care*. 2007 Feb;30(2):203-9.

**Morrato EH**, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ. Prevalence, utilization patterns and predictors of antipsychotic polypharmacy: experience from a Multi-State Medicaid Population (1998-2003). *Clinical Therapeutics*. 2007. Jan;29(1):183-95.

**Morrato EH**, Staffa JA. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data. *Pharmacoepidemiology and Drug Safety*. 2007 16(1):104-12.; doi 10.1002/pds.1279.

McCollum M, Ellis SL, **Morrato EH**, Sullivan PW. Prevalence of multiple cardiovascular risk factors in U.S. adults with diabetes. *Current Medical Research and Opinion*. 2006; 22(4): 1031-1034.

**Morrato EH**, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Are health care professionals advising patients with diabetes or at-risk for developing diabetes to exercise more? *Diabetes Care*. 2006 Mar;29(3):543-8.

Sullivan PW, **Morrato EH**, Ghushchyan V, Wyatt HR, Hill JO. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. *Diabetes Care*. 2005; 28(7): 1599-1603.

### Research Reports

**Morrato EH**, Allen RR, Kempe A. "Colorado Children's Healthcare Access Program (CCHAP): 12-Month Evaluation of the Program (July 1, 2007 – June 30, 2008)" for the Colorado Department of Health Care Policy and Financing. March 2009

**Morrato EH**, Allen RR, Kempe A. "Colorado Children's Healthcare Access Program (CCHAP): Preliminary Evaluation of the Program (July 1, 2007 – December 31, 2007)" for the Colorado Department of Health Care Policy and Financing. October 2008

(b) (4), **Morrato EH**, (b) (4). "An evaluation of the FDA warnings on antidepressants and suicidality on patterns of care for depression in U.S. managed care enrollees" for (b) (4). November 2006.

(b) (4) **Morrato EH**, (b) (4). "Atypical Antipsychotic Treatment Patterns in a Multi-State Medicaid Population (1998-2003)" for (b) (4). March 2006.

(b) (4), **Morrato EH**, (b) (4): a comparison of dosing and titration in community-based clinical practices” for (b) (4). December 2004.

### ***Published and Presented Abstracts***

Barnard JG, **Morrato EH**, Benefield EM, Hadley-Miller NA, Kempe A, Erickson MA. Quality of life for children with neuromuscular scoliosis. Poster presentation at the *2009 Annual Meeting of the International Society for Quality of Life Research*, New Orleans, LA, October 28-31, 2009.

**Morrato EH**, Druss B, Hartung DM, Valuck RJ, Thomas D, Allen RR, Campagna E, Newcomer JW. Determinants of metabolic testing for patients treated with second-generation antipsychotics after the FDA diabetes Warning. Oral presentation at the *25<sup>th</sup> Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Providence, RI, August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*. 2009.

**Morrato EH**, Nicol G, Druss B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic risk mitigation in children receiving antipsychotics. Poster presentation at the *25<sup>th</sup> Anniversary International Conference on Pharmacoepidemiology and Therapeutic Risk Management*, Providence, RI, August 16-19, 2009. *Pharmacoepidemiology and Drug Safety*. 2009.

**Morrato EH**, Druss, B, Hartung DM, Valuck RJ, Allen RR, Campagna E, Newcomer JW. Metabolic testing rates in three state Medicaid programs after FDA Warnings on Antipsychotic Drugs and Diabetes. Poster presentation at the 2009 APA Annual Meeting, San Francisco, CA, May 16-19, 2009.

Barnard JG, Erickson MA, **Morrato EH**, Hadley-Miller NA, Benefield EM, Nowels CT, Kempe A. Managing Surgical Risk and Post-Discharge Needs in Special Needs Children with Neuromuscular Scoliosis: The High-Risk Pathway. Poster presentation at the 2009 Pediatric Academic Societies’ Annual Meeting, Baltimore, MD, May 2-5, 2009.

Erickson MA, Miller N, Kempe A, **Morrato EH**, Benefield E, Benton K. Variability in Spinal Surgery Outcomes among Children’s Hospitals in the U.S. Oral presentation to be presented at the *2009 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting*, Las Vegas, NV, February 25-28, 2009.

Flake C, Johnson L, Orlando V, Bishop F, Wadwa P, Wilson A, Maas, D, **Morrato EH**. Periodontal health status of adolescents with type 1 diabetes. Poster presentation at the 25<sup>th</sup> Annual Research Day at the School of Dental Medicine. February 18, 2009. University of Colorado Denver, Aurora, CO.

**Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic testing after the FDA warning on atypical antipsychotic drugs and diabetes risk. Oral presentation at the *24<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. August 17-20, 2008. Copenhagen, Denmark. *Pharmacoepidemiology and Drug Safety*. 2008 17: S266.

**Morrato EH**, Partrick D, Sullivan PW, Ghushchyan V, Kempe A. Prevalence of reflux disorders and antireflux medication in U.S. children. Poster to be presented at the *24<sup>th</sup> International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. August 17-20, 2008. Copenhagen, Denmark. *Pharmacoepidemiology and Drug Safety*. 2008 17: S204.

**Morrato EH**, Erickson M, Beaty B; Benton K; Benefield E, Kempe, A. Variability in surgical outcomes for spinal fusion surgery in U.S. children’s hospitals. Oral presentation presented at the Health Services Epidemiology Spotlight Session at the *Society for Epidemiology Research Conference*, June 24-27, 2008, Chicago, IL. *Am J Epidemiol*. 2008; 167(Suppl): S40.

Partrick DA, **Morrato EH**, Kempe A, Beaty B, Roach JP, Ziegler MM. National frequency of antireflux procedures and gastrostomy. Analysis of hospital type, patient age, and presence of neurologic impairment. Oral presentation at the *Pacific Association of Pediatric Surgeons 41<sup>st</sup> Annual Meeting*. June 29-July 3, 2008, Jackson Hole, WY.

**Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA Consensus Statement on Antipsychotic Drugs and Risk of Diabetes and Dyslipidemia. Poster presented at the *American Diabetes Association's 68th Scientific Sessions*. June 6-10, 2008, San Francisco, CA. *Diabetes*. 2008; 57(Suppl 1): A279.

**Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Impact of the atypical antipsychotic FDA Warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. Poster to be presented at the *48<sup>th</sup> Annual NCDEU Meeting*, co-sponsored by the National Institute of Mental Health (NIMH) and the American Society of Clinical Psychopharmacology (ASCP). May 27-30, 2008, Phoenix Arizona.

Fox D, **Morrato EH**, Partrick D, Bruny J, Benton K, Kempe A. National trends regarding fundoplication in neurologically impaired children. Poster presented at the *Pediatric Academic Societies' & Asian Society for Pediatric Research Joint Meeting*. Honolulu, HI, May 3-6, 2008.

**Morrato EH**, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Trends in annual metabolic screening for patients taking second-generation antipsychotic medications. Poster presented at the *161<sup>st</sup> Annual Meeting of the American Psychiatric Association Annual Meeting*. May 3-8, 2008, Washington, D.C.

Benefield E, Erickson MA, **Morrato EH**. Implementing a protocol for high risk children undergoing surgery: How do you make it work? Poster presented at the *18<sup>th</sup> Annual Convention of the Society for Pediatric Nurses*. April 4-6, 2008, Denver, CO.

Partrick DA, **Morrato EH**, Roach JP, Ziegler, MM. The national frequency of gastrointestinal pediatric surgery in hospitalized neonates. Oral presentation presented at the 3rd Annual Academic Surgical Congress. February 13-15, 2008, Huntington Beach, CA.

Banta JE, **Morrato EH**, Lee SW. Diabetes care among Medicaid psychiatric patients. *135<sup>th</sup> Annual Meeting of the American Public Health Association*. November 3 – 7, 2007, Washington, D.C.

**Morrato EH**, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J. Effect of metabolic risk status on atypical antipsychotic treatment choice. *160<sup>th</sup> Annual Meeting of the American Psychiatric Association*. May 19-24, 2007, San Diego, CA.

**Morrato EH**, Curbow B, Nowels C, Feinleib M. Physician sources and perceptions of drug risk communication. *Pharmacoepidemiology and Drug Safety*. 2006;15 (Suppl 1): S189.

**Morrato EH**, Feinleib M, Valuck RJ. Changes in liver function testing following the nefazodone boxed warning. *Pharmacoepidemiology and Drug Safety*. 2006;15 (Suppl 1): S139.

**Morrato EH**, Feinleib M, Valuck RJ. Characteristics of nefazodone patients receiving baseline liver function testing. *Pharmacoepidemiology and Drug Safety*. 2006;15 (Suppl 1): S139.

**Morrato EH**, Newcomer JW, Allen RR, and Valuck RJ. Atypical antipsychotics and diabetes testing: a four-state Medicaid study. *Diabetes*. 2006; 55 (Supplement 1).

**Morrato EH**, Newcomer JW, Allen RR, and Valuck RJ on behalf of the Medicaid Pharmacotherapy Research Consortium. Atypical antipsychotics and metabolic screening: a four-state Medicaid study. *159<sup>th</sup>*

*Annual Meeting of the American Psychiatric Association Annual Meeting.* May 20-25, 2006. Toronto, Canada.

RJ Valuck, **EH Morrato**, SL Dodd and RR Allen on behalf of the Medicaid Pharmacotherapy Research Consortium. Antipsychotic utilization: a six-state Medicaid study. *159<sup>th</sup> Annual Meeting of the American Psychiatric Association Annual Meeting.* Toronto, Canada. May 20-25, 2006.

RJ Valuck, **EH Morrato**, SL Dodd and RR Allen on behalf of the Medicaid Pharmacotherapy Research Consortium. Antipsychotic polypharmacy costs: a five-state Medicaid study. *Value in Health.* 2006; 9(3):A70.

Valuck RJ, Libby AM, **Morrato EH**, Oquenda MA, Brown H, Gibbons RD. Antidepressant treatment and risk of suicide attempt by adults with major depressive disorder: a propensity-adjusted retrospective cohort study. *Neuropsychopharmacology.* 2005; 30 (Supplement 1): S242.

McCollum M, Ellis SE, **Morrato EH**, Ghushchyan V, Sullivan PW. Prevalence of cardiovascular risk factors among people with and without diabetes and CHD. *American College of Clinical Pharmacy Annual Meeting.* San Francisco, CA. October 22-26, 2005.

Valuck RJ, **Morrato EH**, Allen R, Dodd S. Atypical antipsychotic treatment patterns in six Medicaid fee-for-service populations. *The 2005 National Medicaid Summit.* Park City, UT. September 29-October 1, 2005.

**Morrato EH**, Feinleib M, Valuck RJ. Impact of nefazodone relabeling: changes in prescriber mix and prescribing volume. *Pharmacoepidemiology and Drug Safety.* 2005; 14 (Supplement 1).

**Morrato EH**, Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. Prevalence of diabetes with increasing adiposity and inactivity in U.S. adults: the Medical Expenditure Panel Survey 2000-2002. *Diabetes.* 2005; 54 (Supplement 1): A259.

**Morrato EH**, Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. Physical activity and diabetes in U.S. adults: the Medical Expenditure Panel Survey 2000-2002. *Diabetes.* 2005; 54 (Supplement 1): A254 .

**Morrato EH**, Valuck RJ. Impact of relabeling on nefazodone prescribing: a risk minimization evaluation. *Value in Health.* 2005; 8(3): 395.

**Morrato EH**, Staffa JA. Analysis of longitudinal claims data to examine first and second-line use of pemoline (Cylert®). *Value in Health.* 2004; 7(3): 282.

**Morrato EH.** Pediatric Drug Labeling Policy: Characteristics of Drugs Granted Exclusivity. *University of Colorado Health Sciences 21<sup>st</sup> Annual Epidemiology Conference*, February 2003.

Kerr, CR, **Morrato, EH**, Humphries, KH et al. Limitations to antiarrhythmic drug use in patients with atrial fibrillation: Insights from the Canadian Registry of Atrial Fibrillation. *North American Society for Pacing and Electrophysiology Conference*, May 2001.

Bhattacharyya SK, Tommondy P, Huber D, **Morrato EH.** Resource utilization for side-effects of antiarrhythmic drugs. *DIA 36th Annual Meeting*, June 2000.

Bhattacharyya SK, Tommondy P, Huber D, **Morrato EH.** Outpatient resource utilization of patients with atrial fibrillation or flutter related to recurrence and maintenance of normal sinus rhythm. *DIA 36th Annual Meeting*, June 2000.



Bhattacharyya SK, **Morrato EH**. Costs of the treatment of side effects of antiarrhythmic drugs in the USA. *International Society for Pharmacoeconomic and Outcomes Research 5th Annual International Meeting*, May, 2000.

### ***Invited Book Reviews***

*Textbook of Pharmacoepidemiology* Edited by Brian L. Strom and Stephen E. Kimmel **Elaine H. Morrato** American Journal of Epidemiology 2007; doi: 10.1093/aje/kwm215

*Wade Hampton Frost, Pioneer Epidemiologist 1880-1938: Up to the Mountain* by Thomas M. Daniel. American Journal of Epidemiology. **Elaine H. Morrato** 2005; 162(3): 290-291.

## **PRESENTATIONS**

“Caregivers’ And Relatives’ Expectations for Spinal Surgery (CARES) Study” with Juli Barnard, Colorado Health Outcomes Research Seminar, University of Colorado Denver, Aurora, CO (February 2009).

“Influences of Individual and Geographic Factors on Drug Safety Practices: Applications for Antipsychotics and Diabetes Risk”, Colorado Health Outcomes Methods and Applications Seminar, University of Colorado Denver, Aurora, CO (January 2009).

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Impact of the atypical antipsychotic FDA Warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. NCDEU CME Poster Session 2008. Best research posters presented at the 2008 NCDEU (New Clinical Drug Evaluation Unit) Meeting. CME Institute, Physicians Postgraduate Press, Inc., *The Journal of Clinical Psychiatry* (October 2008)

Newcomer JW, Haupt D, Morrato EH, Parks J. Why psychiatry is a branch of medicine: an update on screening and monitoring cardiometabolic risk during mental health treatment. Symposium presented at the *60th Institute on Psychiatric Services*. October 2-5, 2008 in Chicago, IL.

“Atypical antipsychotic drugs and metabolic testing: Assessing response to the FDA warnings”, U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Visiting Professor Lecture Series (VPLS), Rockville, MD (July 2008)

“Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: A retrospective, population based study of Medicaid claims data”, Schizophrenia CME E-Journal Club, Editor: John M. Kane, Albert Einstein College of Medicine (May 2008)

“Epidemiology of Pediatric Surgery: Results from KID 2003” with Katie Benton, Colorado Health Outcomes Research Seminar, University of Colorado Denver, Aurora, CO (April 2008)

“Physical Activity in U.S. Adults with Diabetes and At Risk For Developing Diabetes”, Primary Care Edition of the Cardiometabolic E-Journal Club, Editor: Jorge Plutzky, Brigham and Women's Hospital, Harvard Medical School (January 2008)

“Understanding Quality of Life issues for children undergoing spinal fusion surgery for scoliosis: the special case of children with neuromuscular disorders”, Qualitative Methods Research Forum, University of Colorado Denver, Denver, CO (November 2007)

“Drug safety: Can it be managed?” Graduate Summer Institute of Epidemiology and Biostatistics Seminar Series, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (June 2007)

“*PHIS and KID*: Secondary data sources for pediatric hospitalization outcomes”, Colorado Health Outcomes Research Seminar, University of Colorado at Denver and Health Sciences Center, Aurora, CO (April 2007)

“Specificity and sensitivity: Implications for clinical decision making and research” Rehab Science and Engineering Consortium (RSEC) Seminar, University of Colorado at Denver and Health Sciences Center, Denver, CO (April 2007)

“Epidemiology of pediatric surgery” Pediatric national Surgical Quality Improvement Program (NSQIP): protocol development meeting, American College of Surgeons, Chicago, IL (April 2007)

“Evaluating Physician Adoption of FDA Drug Warnings: How do we get the most out of administrative claims data?” Department of Preventive Medicine Research Seminar, University of Colorado at Denver and Health Sciences Center, Denver, CO (January 2007)

“Lessons Learned from Consumer Product Research” Qualitative Research Methods Forum, University of Colorado at Denver and Health Sciences Center, Aurora, CO (November 2006)

“From MEPS to Medicaid: Outcomes Research Learning in Diabetes and Mental Health” Fellowship Seminar, Department of Clinical Pharmacy Seminar Series, University of Colorado at Denver and Health Sciences Center, Denver, CO (July 2006)

“Impact of Nefazodone (Serzone®) Hepatic Risk Minimization Recommendations: A Case Study Evaluation of an FDA Boxed Warning”, Office of Drug Safety Research Seminar, U.S. Food and Drug Administration, Rockville, MD (June 2006)

“Utilization of Retrospective Databases to Inform Evidence Based Drug Policy Making” International Society for Pharmacoeconomics and Outcomes Research 11<sup>th</sup> Annual International Meeting. Philadelphia, PA (May 2006)

“Pharmaceutical Risk Management Evaluation”, Colorado Health Outcomes Methods and Applications Seminar, University of Colorado at Denver and Health Sciences Center, Aurora, CO (February 2006)

“Ethical Issues in Drug Product Risk Assessment and Communication” Western Drug Safety and Pharmacoepidemiology Conference. Napa, CA (October 2005)

“Impact of Relabeling on Nefazodone (Serzone®) Prescribing: A Risk Minimization Evaluation”, First Western Pharmacoeconomics Conference. Salt Lake City, UT (March 2005)

“HELIDAC Therapy: A Newly FDA-Cleared Therapy Designed for Compliance,” International Business Communications Meeting on *H. pylori* (January 1997)

#### **ACADEMIC GRANT AND CONTRACT PARTICIPATION**

2009- Co-Investigator. Center for Native Oral Health Research (CNOHR). Supported by the National Institute of Dental and Craniofacial Research as a Cooperative Research Center (U54). (PI: Judith Albino, PhD)

- 2007- Principal Investigator. Periodontal health status of adolescents with type 1 diabetes. Supported in part by the Children's Research Institute Pilot Award; MO1-RR00069, General Clinical Research Centers Program, NCCR, NIH; a gift from The Procter & Gamble Company; and the Delta Dental Foundation Frontier Center.
- 2006- Assistant Director (2009-) and senior methodologist. Children's Outcomes Research Program. The Children's Hospital Research Institute (PI: (b) (6), MD MPH)
- Co-Investigator. Pediatric Spinal Fusion Surgery at U.S. Children's Hospitals (PI: (b) (6), MD)
- Co-Investigator. Anti-reflux Surgery at US Hospitals (2000-2006) (PI – (b) (6), MD)
- Principal-Investigator. Caregivers' and Relatives' Expectations for Spinal (CARES) Surgery Study
- Principal-Investigator. Epidemiology of Pediatric Surgery in the U.S.
- 2006- Principal Investigator. Evaluating the impact of FDA warnings and consensus recommendations on metabolic screening and monitoring for patients initiating atypical antipsychotic medication: a multi-state Medicaid claims study. (b) (4).
- 2006 Co-Investigator. An evaluation of the FDA warnings on antidepressants and suicidality on patterns of care for depression in U.S. managed care enrollees. (b) (4) (PI – (b) (4), PhD)
- 2005-2006 Principal Investigator. Drug risk communication: physician perceptions. Johns Hopkins Bloomberg School of Public Health, Dissertation Award.
- 2005-2006 Co-Investigator. Atypical antipsychotic treatment patterns in a multi-state Medicaid population. (b) (4) (PI – (b) (4) PhD)

## TEACHING

- 2009 Instructor, Course: Applied Database Research (PHSC 7622). University of Colorado Denver, Aurora, CO.
- 2008 Lecturer, Course: Special Topics in Outcomes Research (PHSC 7570). Topic: FDA, Risk Evaluation and Mitigation Strategies (REMS), and Future Direction for Drug Safety Policy. University of Colorado Denver, Aurora, CO.
- 2008 Lecturer, Course: Database Research Methods (PHSC 7621). Topic: Medicaid Databases. University of Colorado Denver, Aurora, CO.
- 2007 Lecturer, Course: Biostatistics (PHRD 4400). Topic: Study Designs in Clinical Research. University of Colorado at Denver and Health Sciences Center, Denver, CO.
- 2007 Lecturer, Course: Pharmacoepidemiology (340.617.11). Topic: Drug Safety and Risk Management. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 2006-2008 Lecturer, Course: Cost Effectiveness Analysis and Pharmacoeconomics (PHRD 5400). Topic: U.S. Drug Advertising. University of Colorado Denver, Aurora, CO.
- 2005-2008 Lecturer, Course: Health Care Systems (PRMD 6603). Topic: Drug Development and the History of FDA Regulation. University of Colorado Denver, Aurora, CO.
- 2005, 2006 Lecturer, Course: Biostatistics (PHRD 4400). Topic: Categorical Data: Comparing Groups. University of Colorado at Denver and Health Sciences Center, Denver, CO.

- 2005      Lecturer, Course: Biostatistics (PHRD 4400). Topic: Descriptive Statistics. University of Colorado at Denver and Health Sciences Center, Denver, CO.
- 2004      Lecturer, Course: Biostatistics (PHRD 4400). Topic: Hypothesis Testing and Power. University of Colorado at Denver and Health Sciences Center, Denver, CO.
- 2003      Teaching Assistant, Course: Data Analysis Workshops I and II (140.613 and 140.614). Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

***Outcomes Research Methodology Series for The Children's Hospital Surgical Clinical Faculty, coordinating instructor***

- 2008      Evolving FDA Drug Safety Policy and the Case of Trasylol (aprotinin).
- 2007      Defining your research question - What do you really want to know?
- 2007      Principles of Cost Effectiveness
- 2007      Specificity and Sensitivity: Implications for Clinical Practice and Research Studies
- 2006      CONSORT Statement of Good Clinical Research Reporting